EN DE

Centene Corporation (CNC) Fair Value & Analysis

Healthcare · US · Market cap $32.9B

CC Centene Corporation logo Centene Corporation CNC · US
Price$64.20
Fair Value$111.96
Upside+74.4%
Quality65/100
Watch Centene Corporation for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -3.6% net margin
Moderate debt · generates free cash flow
Ranks above peers (9/13)
Narrow moat 24/100
Evidence: Medium Range $77.83 – $146.08 Share as image

Fair value as of: Jul 16, 2026

From 9 valuation models · updated 22 days ago

Share price −2.9% over the past month.

A solid business, screening 74% undervalued on our models.

What matters now

  • The price is below even our cautious bear case ($77.83). The market is more pessimistic than our downside scenario.
  • Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range ($77.83 to $146.08) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$97.22 $25.21 Fair Value $111.96 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range $25.21 – $97.22 · fair‑value band $77.83 – $146.08 · the $64.20 price screens below the $111.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Centene Corporation (CNC) currently trades at $64.20, while our model-based Fair Value estimate is $111.96, implying the stock looks roughly 74.4% undervalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Centene Corporation generated revenue of $178B at a net margin of -3.6%. Revenue grew 5.1% year over year. It earns a return on equity of -26.0%. Net debt stands at $889M. Fundamentals as of Jul 16, 2026

Our scenario range runs from $77.83 (bear case) to $146.08 (bull case); at $64.20, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 156% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 74%, CNC screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF $139.61 $258.76 $499.59 80
Rev-Margin DCF $106.41 $204.53 $388.93 74
Gordon GGM $1.64 $3.40 $5.40 70
All 9 models by family
DCF Models
FCF DCF $148.37 $232.83 $501.81 38
5Y Revenue Exit $105.84 $178.89 $331.48 39
10Y Revenue Exit $116.49 $246.25 $326.20 36
Dividend Discount
Gordon GGM $1.64 $3.40 $5.40 70
DDM Multi-Stage $1.64 $2.87 $3.57 61
Multiples
EV/Revenue $80.72 $114.84 $148.97 43
Asset-Based
NCAV (Graham) $20.20 $27.07 $40.41 50
Growth DCF
Growth DCF $139.61 $258.76 $499.59 80
Rev-Margin DCF $106.41 $204.53 $388.93 74

Widest divergence: DCF Models ($232.83) versus Dividend Discount ($2.87). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) $178B
Revenue growth (YoY) +5.1%
Net margin -3.6%
Return on equity -26.0%
Free cash flow $4.3B FY2025
Operating margin 5.1%
More key figures
EPS (TTM) $-13.05
EPS growth (YoY) +18.3%
Net debt $889M FY2025

Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 65/100

Of which business quality 60 · Market factors (momentum, volatility) 77

Profitability 31
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 43
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 39
Calm price path (market factor)
Momentum 92
Price trend over the last 3–12 months (market factor)
52W Momentum 94
Distance to the 52-week high (market factor)
Net Issuance 100
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.

Full company description

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Centene Corporation reported revenue of $195B in FY2025 versus $126B in FY2021, a compound +11.5%/yr. Reported net income was −$6.7B in FY2025.

Growth Quality 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$195B
Latest YoY
+19.4%
Avg. growth/yr (3Y)
+10.5%
Avg. growth/yr (5Y)
+11.9%
Avg. growth/yr (26Y)
+30.3%
Revenue +11.5%/yr
FY21 $126B
FY22 $145B
FY23 $154B
FY24 $163B
FY25 $195B
Net income
FY21 $1.3B
FY22 $1.2B
FY23 $2.7B
FY24 $3.3B
FY25 −$6.7B

Watch CNC: get an alert when its fair value changes →

Share or link this analysis · shared 8×
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Centene Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CNC

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Healthcare Plans · 15 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Above median
Fair Value upside +74% · Top 25%
Return on assets 1% · Bottom 25%
Net margin (TTM) -4% · Bottom 25%
Operating margin (TTM) 5% · Above median
Revenue growth 5% · Above median
Debt / equity 0.87× · Higher than 75% of peers

Valuation Multiples vs Healthcare Plans median · lower = cheaper

P/B 1.65× · Cheaper than 75% of peers
P/S (TTM) 0.18× · Cheaper than 75% of peers
P/FCF 7.6× · Cheaper than median
EV/EBITDA 11.1× · Cheaper than 75% of peers
PEG 1.32× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 39
FUTURE 26 · sector 23
PAST 0 · sector 41
HEALTH 57 · sector 65
DIVIDEND 0 · sector 0

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Stock Price Fair Value vs Fair Value
UnitedHealth Group UNH $423.38 $292.06 -31%
CVS Health Corporation CVS $104.15 $42.54 -59%
Elevance Health, Inc ELV $372.85 $431.40 +16%
The Cigna Group CI $304.50 $495.42 +63%
Humana Inc HUM $400.00 $127.61 -68%
Molina Healthcare, Inc MOH $233.31 $199.31 -15%
Oscar Health, Inc OSCR $29.10 $58.20 +100%
Alignment Healthcare, Inc ALHC $20.60 $2.37 -88%
Progyny, Inc PGNY $31.93 $16.44 -49%
Bradsaúde S.A SAUD3 R$15.35 R$20.75 +35%

Compare Centene Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Centene Corporation (CNC) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of $111.96 versus a price of $64.20, about +74% (undervalued).
What is the fair value of CNC?
Our model-based fair value for Centene Corporation is $111.96 (as of Jul 16, 2026), built from audited fundamentals. The current price is $64.20.
What is the quality score of CNC?
Centene Corporation has a Quality Score of 65/100. It combines two groups: business quality (profitability, growth, cash flow, balance-sheet strength) and market factors (price momentum, distance to the 52-week high, volatility). Both subtotals are shown separately in the detail view.
What is the revenue of Centene Corporation (CNC)?
Centene Corporation reported trailing-twelve-month revenue of about $178B (latest available figure, as of Jul 16, 2026).
What is the net profit margin of CNC?
The net profit margin of Centene Corporation is about -3.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Centene Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.